However, another second-generation potent FLT3 inhibitor active against both FLT3-ITD and FLT3-TKD mutations, currently FDA approved in the R/R AML setting, is gilteritinib, based on the ADMIRAL trial [50]. Here, FLT3 is linked to acute myeloid leukemia.